BlueRock Therapeutics and Foundation Fighting Blindness collaborate to add new cohort to Uni-Rare study evaluating inherited retinal diseases
The new cohort will add patients living with IRDs caused by mutations in multiple genes to the already existing cohort of patients with IRDs caused by single gene mutations.